Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
7289 patients.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In the United States, current ICI-based therapies are not cost-effective at existing prices. These findings may inform treatment selection and health policy decision-making in different healthcare systems.
[BACKGROUND] Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of advanced or unresectable hepatocellular carcinoma (HCC).
- 연구 설계 meta-analysis
APA
Qi H, Huang Y, et al. (2026). Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis.. Therapeutic advances in medical oncology, 18, 17588359261417630. https://doi.org/10.1177/17588359261417630
MLA
Qi H, et al.. "Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis.." Therapeutic advances in medical oncology, vol. 18, 2026, pp. 17588359261417630.
PMID
41804358 ↗
Abstract 한글 요약
[BACKGROUND] Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of advanced or unresectable hepatocellular carcinoma (HCC). However, the comparative clinical efficacy and cost-effectiveness of various ICI-based combination therapies remain unclear.
[OBJECTIVES] This study aimed to evaluate the cost-effectiveness and clinical efficacy of the 12 first-line ICI-based therapies for advanced or unresectable HCC under two distinct healthcare systems-China and the United States.
[DESIGN] A model-based pharmacoeconomic analysis.
[METHODS] A network meta-analysis (NMA) was conducted to compare first-line ICI-based therapies in terms of overall survival (OS) and progression-free survival (PFS). A partitioned survival model with three health states (progression-free, progressive disease, death) was developed for cost-effectiveness analysis. Quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) were primary outcomes. One-way and probabilistic sensitivity analyses were performed to assess model uncertainty.
[RESULTS] The NMA included 11 randomized clinical trials comprising 7289 patients. Four ICI-based regimens (atezolizumab plus bevacizumab, camrelizumab plus rivoceranib, sintilimab plus bevacizumab biosimilar, and penpulimab plus anlotinib) were associated with significantly improved OS and PFS compared with sorafenib. In China, camrelizumab plus rivoceranib and tislelizumab were cost-effective compared with sorafenib, with ICERs of $17,624.64 and $1971.14 per QALY, respectively. In the United States, no ICI-based therapy was cost-effective at a willingness-to-pay threshold of $150,000 per QALY; sorafenib remained the most cost-effective option. ICERs were most sensitive to drug costs, utility values, and discount rates.
[CONCLUSION] Camrelizumab plus rivoceranib represents a cost-effective first-line therapy for advanced or unresectable HCC in China. In the United States, current ICI-based therapies are not cost-effective at existing prices. These findings may inform treatment selection and health policy decision-making in different healthcare systems.
[OBJECTIVES] This study aimed to evaluate the cost-effectiveness and clinical efficacy of the 12 first-line ICI-based therapies for advanced or unresectable HCC under two distinct healthcare systems-China and the United States.
[DESIGN] A model-based pharmacoeconomic analysis.
[METHODS] A network meta-analysis (NMA) was conducted to compare first-line ICI-based therapies in terms of overall survival (OS) and progression-free survival (PFS). A partitioned survival model with three health states (progression-free, progressive disease, death) was developed for cost-effectiveness analysis. Quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) were primary outcomes. One-way and probabilistic sensitivity analyses were performed to assess model uncertainty.
[RESULTS] The NMA included 11 randomized clinical trials comprising 7289 patients. Four ICI-based regimens (atezolizumab plus bevacizumab, camrelizumab plus rivoceranib, sintilimab plus bevacizumab biosimilar, and penpulimab plus anlotinib) were associated with significantly improved OS and PFS compared with sorafenib. In China, camrelizumab plus rivoceranib and tislelizumab were cost-effective compared with sorafenib, with ICERs of $17,624.64 and $1971.14 per QALY, respectively. In the United States, no ICI-based therapy was cost-effective at a willingness-to-pay threshold of $150,000 per QALY; sorafenib remained the most cost-effective option. ICERs were most sensitive to drug costs, utility values, and discount rates.
[CONCLUSION] Camrelizumab plus rivoceranib represents a cost-effective first-line therapy for advanced or unresectable HCC in China. In the United States, current ICI-based therapies are not cost-effective at existing prices. These findings may inform treatment selection and health policy decision-making in different healthcare systems.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Integrated nomogram for predicting intracranial progression-free survival with EGFR-TKI combined with cranial radiotherapy: a multicenter study.
- Unraveling pancreatic ductal adenocarcinoma at single-cell resolution with spatial insights: From mechanisms to clinical translation.
- The progress of biomarkers detection to lung cancer.
- A narrative review of the early diagnosis and treatment of idiopathic pulmonary fibrosis with lung cancer.
- KNTC1 functions as a potential biomarker and oncogene regulating proliferation, migration and apoptosis in gastric cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Reforming the delivery of smoking cessation: a distributional cost-effectiveness analysis of providing smoking cessation as part of targeted lung cancer screening.
- Heat Shock Protein 47 as a Novel Predictive and Diagnostic Biomarker for Thrombosis in Hepatocellular Carcinoma.
- Crosstalk Between -Regulatory Elements and Metabolism Reprogramming in Hepatocellular Carcinoma.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- Risks, Benefits, and Molecular Targets of Fenugreek Administration in the Treatment of Hepatocellular Carcinoma.